Benoit R M, Cohen J K, Miller R J
Department of Urology, Allegheny General Hospital, 1209 Allegheny Tower, 625 Stanwix Street, Pittsburgh, PA 15222, USA.
Curr Urol Rep. 2000 May;1(1):41-7. doi: 10.1007/s11934-000-0034-0.
Patients diagnosed with prostate cancer who elect to pursue active treatment of their disease must choose among the many available treatment alternatives. Several treatment options now exist for similar-stage disease (clinical T1-3N0M0), including radical prostatectomy, external beam radiation, prostate brachytherapy (PB), and cryosurgical ablation of the prostate (CSAP). This article reviews the current role of CSAP in the treatment of clinically localized prostate cancer. CSAP has a role in the primary treatment of men with high-risk, clinically localized prostate cancer (defined as PSA >10, Gleason score >or=7, or clinical stage >or= cT2B). CSAP (occasionally followed by external beam radiotherapy) appears to offer improved rates of cancer control over other types of single or combination therapies for this high-risk prostate cancer, and it is associated with an acceptable side-effect profile. CSAP should also be the treatment of choice for men with recurrent local disease who have undergone external beam radiotherapy or PB.
被诊断患有前列腺癌且选择积极治疗疾病的患者必须在众多可用的治疗方案中做出选择。对于相似分期的疾病（临床T1 - 3N0M0），目前有几种治疗选择，包括根治性前列腺切除术、外照射放疗、前列腺近距离放射治疗（PB）以及前列腺冷冻消融术（CSAP）。本文综述了CSAP在临床局限性前列腺癌治疗中的当前作用。CSAP在高危临床局限性前列腺癌（定义为PSA > 10、Gleason评分≥7或临床分期≥cT2B）男性的初始治疗中具有作用。对于这种高危前列腺癌，CSAP（偶尔联合外照射放疗）似乎比其他类型的单一或联合治疗能提供更高的癌症控制率，并且其副作用可接受。CSAP也应是接受过外照射放疗或PB后局部疾病复发男性的首选治疗方法。
